We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AACC Releases Guidelines on Point-of-Care Testing for Non-Laboratorians

By LabMedica International staff writers
Posted on 14 Sep 2022

Point-of-care testing (POCT), or near-patient testing, is diagnostic testing conducted close to the patient, often by clinical personnel outside of the laboratory. More...

POCT is regularly performed by personnel without a laboratory science degree or credentialing in laboratory medicine. Now, a new guidance document is available for non-laboratorians who are involved in setting up a process or physical space designed to provide testing at or near where patient care is provided.

The guide released by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) presents the challenges to consider when selecting and implementing diagnostic testing. It provides an overview of POCT, including a discussion of the cost-benefit analysis of implementing POCT and the use of POCT in various healthcare settings. The AACC guide presents the challenges to consider when selecting and implementing POCT. It also offers tools to address and manage those challenges and offers solutions to overcome barriers faced in various settings to ensure quality test results that are reliable for patient care.

The AACC guide includes addenda, including glossaries, templates, and forms, to serve as tools in the implementation of POCT. These are for reference use only; individual POCT laboratories may have unique needs. The guide is not meant to be an all-inclusive ‘how to’ set up a POCT laboratory and is to be used as supportive instruction and education to implement good laboratory practices, according to the AACC. The guide is most helpful when used in conjunction with all information provided by the test manufacturer, including the Manufacturer’s Instructions for Use (MIFU) for testing materials, products, and devices that one has selected to provide laboratory testing services to patients.

Related Links:
AACC 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.